By Fineline Cube 
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing agreement granting SteinCares exclusive commercialization rights to Bio-Thera’s BAT2406, a biosimilar of Sanofi’s Dupixent (dupilumab), for Brazil and other Latin American regions.
Deal Details
The agreement includes a total potential value of up to USD 10 million, comprising a USD 1 million upfront payment, up to USD 9 million in milestone payments, and tiered royalties based on net sales. This marks the fourth biosimilar collaboration between Bio-Thera and SteinCares, following previous deals for BAT2506 (golimumab), BAT2606 (mepolizumab), and BAT2306 (secukinumab).
Drug Profile
BAT2406 is a fully human monoclonal antibody (IgG4) developed according to biosimilar guidelines in China, the US, and the European Union. It inhibits IL-4 and IL-13 signaling by binding to the IL-4Rα subunit. The drug is nearing Phase I clinical trials in China after receiving clearance from the National Medical Products Administration (NMPA).-Fineline Info & Tech